Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCapital LeasesCash & Current InvestmentsCash & EquivalentsCommon EquityConstruction in ProgressCurrent AssetsCurrent Deferred RevenueCurrent LeasesInventoryLiabilities and Shareholders EquityMinority InterestNon-Current AssetsNon-Current DebtNon-Current Deffered RevenueOperating LeasesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesRetained EarningsShareholder's EquityShares OutstandingTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Apyx Medical (APYX) Non-Current Debt (2016 - 2025)

Apyx Medical's Non-Current Debt history spans 13 years, with the latest figure at $34.8 million for Q4 2025.

  • For Q4 2025, Non-Current Debt rose 2.82% year-over-year to $34.8 million; the TTM value through Dec 2025 reached $34.8 million, up 2.82%, while the annual FY2025 figure was $34.8 million, 2.82% up from the prior year.
  • Non-Current Debt reached $34.8 million in Q4 2025 per APYX's latest filing, up from $34.6 million in the prior quarter.
  • In the past five years, Non-Current Debt ranged from a high of $34.8 million in Q4 2025 to a low of $9.0 million in Q3 2023.
  • Average Non-Current Debt over 3 years is $31.5 million, with a median of $33.9 million recorded in 2024.
  • The largest YoY upside for Non-Current Debt was 275.77% in 2024 against a maximum downside of 2.13% in 2024.
  • A 3-year view of Non-Current Debt shows it stood at $33.2 million in 2023, then grew by 2.13% to $33.9 million in 2024, then grew by 2.82% to $34.8 million in 2025.
  • Per Business Quant, the three most recent readings for APYX's Non-Current Debt are $34.8 million (Q4 2025), $34.6 million (Q3 2025), and $34.4 million (Q2 2025).